Skip to main content
. Author manuscript; available in PMC: 2011 Jul 18.
Published in final edited form as: Cancer Cell. 2011 Jan 18;19(1):72–85. doi: 10.1016/j.ccr.2010.11.011

Figure 7. Vaccination in autochthonous lung tumor model reduces tumor burden and promotes loss of antigen expression.

Figure 7

(A and B) Tumor number on the lungs of mice with Lenti-x or Lenti-LucOS tumors 16 weeks after tumor initiation with or without prior DC2.4-LucOS vaccination. p-values are ~0.50 and ~0.0008, respectively.

(C) Freshly explanted Lenti-LucOS tumors were assayed for luciferase activity and the percent of tumors that were luciferase positive (> 50 RLU/μg protein) +/- DC2.4-LucOS vaccination is plotted. n= 5–6 mice, 27–34 tumors, per group.

(D) Representative FACS plots of SIY/Kb-specific T cells (gated on CD8) from the lung and DLN +/- DC2.4-LucOS vaccination, 9 days after tumor initiation with Lenti-LucOS. n≥ 2 mice per group.

(E) FACS for surface-exposed CD107a and captured IFNγ (gated on CD8) after stimulation of DLN cells with SIY and SIN from Lenti-LucOS or Lenti-x tumor-bearing mice +/− DC2.4-LucOS vaccination (16 weeks post tumor initiation). Mean fluorescent intensities of CD107a and IFNγ on reactive T cells is plotted. n= 2–4 mice per group.

(F) FACS analysis of CD8+ anti-SIY/Kb+- and anti-SIN/Kb+-specific T cells for CD127 and CD44 surface expression from the lungs or DLN of Lenti-LucOS or Lenti-x tumor-bearing mice +/− DC2.4-LucOS vaccination (8 weeks post tumor initiation, n= 2–3 mice per group). The ratio of CD44+CD127+ (memory-like) to CD44+CD127− (effector-like) is shown below each FACS plot.

(G) Lenti-LucOS tumors from mice 8 weeks after tumor initiation and 24 hours after transfer of SIY-reactive, CFSE-labeled activated T cells (green) +/− DC2.4-LucOS vaccination. DAPI counter stained. Tumors are outlined. Scale = 50μm.

(H) Mean tumor area of Lenti-LucOS lung tumors at 16, 24 and 30 weeks after tumor initiation +/− DC2.4-LucOS vaccination. p-values are ~0.050, ~0.038, and ~0.027, respectively, from n= 3–10 mice, 70–506 tumors, per group at 16 and 24 weeks, and n= 1–2 mice, 15–46 tumors, per group at 30 weeks.

(I) Percent of Lenti-LucOS tumors/mouse containing infiltrating lymphocytes at 16, 24 and 30 weeks after tumor initiation +/− DC2.4-LucOS vaccination (analysis of mice from H).

Data are mean ± SEM. See also Figure S7.